Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNGB 2904 is a potent and selective dopamine D3 receptor antagonist (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, α1, D4, D1 and D5 receptors respectively). Potently antagonizes quinpirole-stimulated mitogenesis (IC50 = 6.8 nM). Attenuates cocaine's rewarding effects and inhibits relapse to drug-seeking behavior.
NGB 2904 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 530.92 |
公式 | C28H29Cl2N3O.HCl |
储存 | Desiccate at +4°C |
纯度 | ≥98% (HPLC) |
CAS Number | 189061-11-8 |
PubChem ID | 19366304 |
InChI Key | PFIWYJNBKGCVFM-UHFFFAOYSA-N |
Smiles | Cl.ClC1=C(Cl)C(=CC=C1)N1CCN(CCCCNC(=O)C2=CC=C3C(CC4=CC=CC=C34)=C2)CC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 13.27 | 25 | |
ethanol | 2.65 | 5 |
以下数据基于产品分子量 530.92。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.25 mM | 7.53 mL | 37.67 mL | 75.34 mL |
1.25 mM | 1.51 mL | 7.53 mL | 15.07 mL |
2.5 mM | 0.75 mL | 3.77 mL | 7.53 mL |
12.5 mM | 0.15 mL | 0.75 mL | 1.51 mL |
参考文献是支持产品生物活性的出版物。
Yuan et al (1998) NGB 2904 and NGB 2849: two highly selective DA D3 receptor antagonists. Bioorg.Med.Chem.Lett. 8 2715 PMID: 9873609
Xi et al (2006) The novel DA D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31 1393 PMID: 16205781
Pritchard et al (2007) The DA D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol.Biochem.Behav. 86 718 PMID: 17408730
If you know of a relevant reference for NGB 2904, please let us know.
关键词: NGB 2904, NGB 2904 supplier, Potent, selective, D3, antagonists, Dopamine, Receptors, dopaminergic, NGB2904, 2635, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 NGB 2904 的部分引用包括:
Nagata et al (2019) Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells. Sci Rep 9 16438 PMID: 31712714
Axel et al (2010) Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and DA D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35 1464 PMID: 20200509
您是否知道使用了 Tocris NGB 2904 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review NGB 2904 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.